{"id":"quadrivalent-influenza-vaccine-no-preservative","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site soreness or erythema"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The quadrivalent influenza vaccine contains inactivated viral antigens from two influenza A strains (H1N1 and H3N2) and two influenza B strains. When administered, it triggers both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells that recognize and neutralize circulating influenza viruses during the flu season.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:03.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT04551677","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT04109222","phase":"PHASE4","title":"Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-30","conditions":"Influenza","enrollment":90},{"nctId":"NCT05050318","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-09-08","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT02451358","phase":"PHASE3","title":"Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-07-27","conditions":"Influenza","enrollment":400},{"nctId":"NCT03546192","phase":"PHASE4","title":"Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-06-17","conditions":"Influenza","enrollment":120},{"nctId":"NCT02915302","phase":"PHASE4","title":"Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-09-23","conditions":"Influenza","enrollment":1950},{"nctId":"NCT02908269","phase":"PHASE4","title":"Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-09-15","conditions":"Influenza","enrollment":180},{"nctId":"NCT03453801","phase":"PHASE1","title":"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-09-30","conditions":"Influenza, Healthy","enrollment":80},{"nctId":"NCT02563093","phase":"PHASE4","title":"Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":208},{"nctId":"NCT02539108","phase":"PHASE4","title":"Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-08","conditions":"Influenza","enrollment":60},{"nctId":"NCT02222870","phase":"PHASE4","title":"Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-08","conditions":"Influenza","enrollment":60},{"nctId":"NCT01240746","phase":"PHASE3","title":"Study of Quadrivalent Influenza Vaccine Among Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-11","conditions":"Influenza","enrollment":4363},{"nctId":"NCT01946425","phase":"PHASE4","title":"Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-09","conditions":"Influenza","enrollment":60},{"nctId":"NCT00988143","phase":"PHASE2","title":"A Study of Influenza Virus Vaccines in Children and Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-10","conditions":"Influenza","enrollment":600},{"nctId":"NCT01218646","phase":"PHASE3","title":"Study of Quadrivalent Influenza Vaccine Among Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":739}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Quadrivalent Influenza Vaccine, No Preservative","genericName":"Quadrivalent Influenza Vaccine, No Preservative","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}